| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Sino Biopharmaceutical Limited (HK: 1177)
1177 Technical Analysis
5
| As on 13th Jun 2025 1177 STOCK Price closed @ 5.53 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 3.09 & Strong Buy for SHORT-TERM with Stoploss of 3.12 we also expect STOCK to react on Following IMPORTANT LEVELS. |
1177STOCK Price
| Open | 5.78 | Change | Price | % |
| High | 5.78 | 1 Day | -0.16 | -2.81 |
| Low | 5.32 | 1 Week | 0.91 | 19.70 |
| Close | 5.53 | 1 Month | 1.62 | 41.43 |
| Volume | 393679686 | 1 Year | 2.20 | 66.07 |
| 52 Week High 4.77 | 52 Week Low 2.34 | ||||
HK Hong Kong Most Active Stocks
| 1033-OL | 0.80 | 25.00% |
| 1033 | 0.80 | 25.00% |
| 0467 | 0.54 | 22.73% |
| 0568 | 4.04 | 75.65% |
| CSHK100 | 2090.72 | -0.74% |
| 3988 | 4.57 | -1.72% |
| 1060 | 1.01 | -1.94% |
| 0020 | 1.41 | -4.08% |
| 0020-OL | 1.41 | -4.08% |
| 43 | 1.14 | 0.00% |
HK Hong Kong Top Gainers Stocks
HK Hong Kong Top Losers Stocks
| 1177 Daily Charts |
1177 Intraday Charts |
Whats New @ Bazaartrend |
1177 Free Analysis |
|
|
1177 Important Levels Intraday
| RESISTANCE | 6.42 |
| RESISTANCE | 6.13 |
| RESISTANCE | 5.96 |
| RESISTANCE | 5.78 |
| SUPPORT | 5.28 |
| SUPPORT | 5.10 |
| SUPPORT | 4.93 |
| SUPPORT | 4.64 |
1177 Forecast June 2025
| 4th UP Forecast | 6.94 |
| 3rd UP Forecast | 6.49 |
| 2nd UP Forecast | 6.21 |
| 1st UP Forecast | 5.93 |
| 1st DOWN Forecast | 5.13 |
| 2nd DOWN Forecast | 4.85 |
| 3rd DOWN Forecast | 4.57 |
| 4th DOWN Forecast | 4.12 |
1177 Weekly Forecast
| 4th UP Forecast | 6.44 |
| 3rd UP Forecast | 6.15 |
| 2nd UP Forecast | 5.97 |
| 1st UP Forecast | 5.79 |
| 1st DOWN Forecast | 5.27 |
| 2nd DOWN Forecast | 5.09 |
| 3rd DOWN Forecast | 4.91 |
| 4th DOWN Forecast | 4.62 |
1177 Forecast2025
| 4th UP Forecast | 12.26 |
| 3rd UP Forecast | 10.1 |
| 2nd UP Forecast | 8.77 |
| 1st UP Forecast | 7.43 |
| 1st DOWN Forecast | 3.63 |
| 2nd DOWN Forecast | 2.29 |
| 3rd DOWN Forecast | 0.96 |
| 4th DOWN Forecast | -1.2 |
Sino Biopharmaceutical Limited ( HK Hong Kong Symbol : 1177 )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
1177 Business Profile
Sino Biopharmaceutical Limited, an investment holding company, together with its subsidiaries, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates in three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's principal products include hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; oncology medicines comprising Saiweijian injections, Qingkeshu tablets, Qianping injections, Anxian capsules, Yinishu tablets, Genike capsules, Shoufu tablets, Jizhi tablets, and Leweixin injection; cardio-cerebral medicines, including Yilunping tablets, Tuotuo tablets, Sacubatro/Valsartan tablets, Tolvaptan tablets, Rivaroxaban tablets, Edaravone injections, Esmolol Hydrochloride injections, Esmolol Hydrochloride and Sodium Chloride injections, Polidocanol injections, Sacubitril Valsartan Sodium tablets, Urapidil Hydrochloride injections, and Kaina tablets; and orthopedic medicines, such as Gaisanchun capsules, Taiyan tablets, Zoledronic Acid injections, and Yigu injections. Its principal products also comprise digestive system medicines that consists of Aisuping injections, Getai tablets, and Deyou granules; anti-infectious medicines that include Tianjie injections, Fengruineng injections, Tianli injections, and Tianming injections; respiratory system medicines, such as Tianqingsule inhalation powder; and others comprising Debaian cataplasms, and Qingliming injections. In addition, the company engages in property holding activities; the retail and distribution of pharmaceutical products; optometry for optical glasses and sale of ophthalmic products; the provision of medical management consultancy services; and outpatient and surgical procedure. Further, it manufactures, sells, and distributes health food; and develops medical technology. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong. Address: Office Tower, Wan Chai, Hong Kong
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service